Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

This study is currently recruiting participants.
Verified October 2012 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01537432
First received: February 17, 2012
Last updated: October 1, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2014
  Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)